Successful treatment of pityriasis rubra pilaris with adalimumab - case report.

Abstract

Pityriasis Rubra Pilaris (PRP) is an uncommon skin disorder characterized by follicular keratosis, palmoplantar keratoderma, and erythroderma. The traditional preferred treatment is oral retinoids, but over the last decade, biologic therapy with anti-TNF agents has been used with success. We report the case of a 51 year- old man with a clinical and histopathological diagnosis of PRP. He underwent therapy with adalimumab and showed clearance of skin lesions within the fourth week of treatment.

• Authors: Erick A Bravo, Leonidas Carrion, Silvia M Paucar, Rossana Mendoza, Carlos Rivera
• Journal: Dermatology online journal (Dermatol Online J) Vol. 20 Issue 4 Pg. 22374 (Apr 16 2014) ISSN: 1087-2108 [Electronic] United States
• PMID: 24746310 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Dermatologic Agents
• Tumor Necrosis Factor-alpha
• Adalimumab

Topics

• Adalimumab
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Dermatologic Agents (therapeutic use)
• Humans
• Male
• Middle Aged
• Pityriasis Rubra Pilaris (drug therapy, pathology)
• Skin (pathology)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)